Chemotherapy-related cognitive impairment: Neuroimaging, neuropsychological testing, and the neuropsychologist

Clinical Journal of Oncology Nursing

Volumn 13, Issue 4, 2009, Pages 413-421

  Myers, Jamie S ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CHEMICALLY INDUCED DISORDER; COGNITION; COGNITIVE DEFECT; DRUG EFFECT; HUMAN; NEOPLASM; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NURSING; ONCOLOGY NURSING; POSITRON EMISSION TOMOGRAPHY;

ANTINEOPLASTIC AGENTS; COGNITION; COGNITION DISORDERS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASMS; NEUROPSYCHOLOGICAL TESTS; ONCOLOGIC NURSING; POSITRON-EMISSION TOMOGRAPHY;

EID: 77956176452     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/09.CJON.413-421     Document Type: Article

References (54)

1. Ahles, T.A., & Saykin, A. (2001). Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Investigation, 19(8), 812-820.
2. Ahles, T.A., & Saykin, A. (2002). Breast cancer chemotherapy-related cognitive dysfunction. Clinical Breast Cancer, 3(Suppl. 3), S84-S90.
3. Ahles, T.A., & Saykin, A.J. (2007). Candidate mechanisms for chemotherapy- induced cognitive changes. Nature Reviews Cancer, 7(3), 192-201.
4. Ahles, T.A., Saykin, A.J., Furstenberg, C.T., Cole, B., Mott, L.A., Skalla, K., et al. (2002). Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. Journal of Clinical Oncology, 20(2), 485-493.
5. American Psychological Association. (2004). Official position of the division of clinical neuropsychology on the role of neuropsychologists in clinical use of fMRI: Approved by the Division 40 Executive Committee July 28, 2004. Clinical Neuropsychologist, 18(3), 349-351.
6. Barsevick, A.M. (2007). The elusive concept of the symptom cluster. Oncology Nursing Forum, 34(5), 971-980.
7. Brown, M.S., Simon, J.H., Stemmer, S.M., Stears, J.C., Scherzinger, A., Cagnoni, P.J., et al. (1995). MR and proton spectroscopy of white matter disease induced by high-dose chemotherapy with bone marrow transplant in advanced breast carcinoma. American Journal of Neuroradiology, 16(10), 2013-2020.
8. Brown, M.S., Stemmer, S.M., Simon, J.H., Stears, J.C., Jones, R.B., Cagnoni, P.J., et al. (1998). White matter disease induced by high-dose chemotherapy: Longitudinal study with MR imaging and proton spectroscopy. American Journal of Neuroradiology, 19(2), 217-221.
9. Butt, Z., Wagner, L.I., Beaumont, J.L., Paice, J.A., Peterman, A.H., Shevrin, D., et al. (2008). Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. Journal of Pain and Symptom Management, 35(1), 20-30.
10. Castellon, S.A., Ganz, P.A., Bower, J.E., Petersen, L., Abraham, L., & Greendale, G.A. (2004). Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. Journal of Clinical and Experimental Neuropsychology, 26(7), 955-969.
11. Chen, Y., Jungsuwadee, P., Vore, M., Butterfield, D.A., & St. Clair, D.K. (2007). Collateral damage in cancer chemotherapy: Oxidative stress in nontargeted tissues. Molecular Interventions, 7(3), 147-156.
12. Cimprich, B., So, H., Ronis, D.L., & Trask, C. (2005). Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psychooncology, 14(1), 70-78.
13. Cleeland, C.S., Bennett, G.J., Dantzer, R., Dougherty, P.M., Dunn, A.J., Myers, C.A., et al. (2003). Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer, 97(11), 2919-2925.
14. Dietrich, J., Han, R., Yang, Y., Mayer-Proschel, M., & Noble, M. (2006). CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. Retrieved June 18, 2009, from http://jbiol.com/content/pdf/jbiol50.pdf
15. Dietrich, J., Monje, M., Wefel, J., & Meyers, C. (2008). Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist, 13(12), 1285-1295.
16. Dodd, M.J., Miaskowski, C., & Paul, S.M. (2001). Symptom clusters and their effect on the functional status of patients with cancer. Oncology Nursing Forum, 28(3), 465-470.
17. Ferguson, R.J., Ahles, T.A., Saykin, A.J., McDonald, B.C., Furstenberg, C.T., Cole, B., et al. (2007). Cognitive-behavioral management of chemotherapy- related cognitive change. Psychooncology, 16(8), 772-777.
18. Ferguson, R.J., McDonald, B.C., Saykin, A.J., & Ahles, T.A. (2007). Brain structure and function differences in monozygotic twins: Possible effects of breast cancer chemotherapy. Journal of Clinical Oncology, 25(25), 3866-3870.
19. Freeman, J.R., & Broshek, D.K. (2002). Assessing cognitive dysfunction in breast cancer: What are the tools? Clinical Breast Cancer, 3(Suppl. 3), S91-S99.
20. Grober, S.E. (2002). Resources for treatment of chemotherapy-related cognitive difficulty. Cancer Practice, 10(4), 216-218.
21. Han, R., Yang, Y.M., Dietrich, J., Luebke, A., Mayer-Proschel, M., & Noble, M. (2008). Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. Retrieved June 18, 2009, from http://jbiol.com/content/pdf/jbiol69.pdf
22. Hess, L.M., & Insel, K.C. (2007). Chemotherapy-related change in cognitive function: A conceptual model. Oncology Nursing Forum, 34(5), 981-994.
23. Inagaki, M., Yoshikawa, E., Matsuoka, Y., Sugawara, Y., Nakano, T., Akechi, T., et al. (2007). Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer, 109(1), 146-156.
24. Jansen, C.E., Miaskowski, C., Dodd, M., & Dowling, G. (2005). Chemotherapy-induced cognitive impairment in women with breast cancer: A critique of the literature. Oncology Nursing Forum, 32(2), 329-342.
25. Jansen, C.E., Miaskowski, C., Dodd, M., Dowling, G., & Kramer, J. (2005a). A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer, 104(10), 2222-2233.
26. Jansen, C.E., Miaskowski, C., Dodd, M., Dowling, G., & Kramer, J. (2005b). Potential mechanisms for chemotherapy-induced impairments in cognitive function. Oncology Nursing Forum, 32(6), 1151-1163.
27. Kim, H.J., McGuire, D.B., Tulman, L., & Barsevick, A.M. (2005). Symptom clusters: Concept analysis and clinical implications for cancer nursing. Cancer Nursing, 28(4), 270-282.
28. Klemp, J.R., Stanton, A.L., Kimler, B.F., & Fabian, C.J. (2006, October). Evaluating the effects of chemotherapy on cognitive function and quality of life in pre-menopausal women with breast cancer. Poster presented at the meeting of the San Antonio Breast Cancer Symposium, San Antonio, TX.
29. Kreukels, B.P., Schagen, S.B., Ridderinkhof, K.R., Boogerd, W., Hamburger, H.L., Muller, M.J., et al. (2006). Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: An electrophysiologic study. Clinical Breast Cancer, 7(1), 67-78.
30. Lee, B.N., Dantzer, R., Langley, K.E., Bennett, G.J., Dougherty, P.M., Dunn, A.J., et al. (2004). A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation, 11(5), 279-292.
31. Mancuso, A., Migliorino, M., De Santis, S., Saponiero, A., & De Marinis, F. (2006). Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Annals of Oncology, 17(1), 146-150.
32. Massa, E., Madeddu, C., Lusso, M.R., Gramignano, G., & Mantovani, G. (2006). Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. Critical Reviews in Oncology/Hematology, 57(2), 175-182.
33. Meyers, C.A. (2000). Neurocognitive dysfunction in cancer patients. Oncology, 14(1), 75-79.
34. Meyers, C.A., & Wefel, J.S. (2003). The use of the Mini-Mental State Examination to assess cognitive functioning in cancer trials: No ifs, ands, buts, or sensitivity. Journal of Clinical Oncology, 21(19), 3557-3558.
35. Miaskowski, C., Cooper, B.A., Paul, S.M., Dodd, M., Lee, K., Aouizerat, B.E., et al. (2006). Subgroups of patients with cancer with different symptom experiences and quality-of-life outcomes: A cluster analysis [Online exclusive]. Oncology Nursing Forum, 33(5), E79-E89. Retrieved June 18, 2009, from http://ons.metapress.com/content/45j041752130j582/fulltext.pdf
36. Minisini, A., Atalay, G., Bottomley, A., Puglisi, F., Piccart, M., & Biganzoli, L. (2004). What is the effect of systemic anticancer treatment on cognitive function? Lancet Oncology, 5(5), 273-282.
37. Olin, J.J. (2001). Cognitive function after systemic therapy for breast cancer. Oncology, 15(5), 613-618.
38. O'Shaughnessy, J. (2003). Chemotherapy-related cognitive dysfunction in breast cancer. Seminars in Oncology Nursing, 19(4, Suppl. 2), 17-24.
39. Parnet, P., Kelley, K.W., Bluthe, R.M., & Dantzer, R. (2002). Expression and regulation of interleukin-1 receptors in the brain. Role in cytokines-induced sickness behavior. Journal of Neuroimmunology, 125(1-2), 5-14.
40. Pollmacher, T., Haack, M., Schuld, A., Reichenberg, A., & Yirmiya, R. (2002). Low levels of circulating inflammatory cytokines-Do they affect human brain functions? Brain, Behavior, and Immunity, 16(5), 525-532.
41. Saykin, A.J., Ahles, T.A., & McDonald, B.C. (2003). Mechanisms of chemotherapy-induced cognitive disorders: Neuropsychological, pathophysiological, and neuroimaging perspectives. Seminars in Clinical Neuropsychiatry, 8(4), 201-216.
42. Schagen, S.B., Muller, M.J., Boogerd, W., & van Dam, F.S. (2002). Cognitive dysfunction and chemotherapy: Neuropsychological findings in perspective. Clinical Breast Cancer, 3(Suppl. 3), S100-S108.
43. Schagen, S.B., van Dam, F.S., Muller, M.J., Boogerd, W., Lindeboom, J., & Bruning, P.F. (1999). Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer, 85(3), 640-650.
44. Servaes, P., Verhagen, C.A., & Bleijenberg, G. (2002). Relations between fatigue, neuropsychological functioning, and physical activity after treatment for breast carcinoma: Daily self-report and objective behavior. Cancer, 95(9), 2017-2026.
45. Silberfarb, P.M. (1983). Chemotherapy and cognitive defects in cancer patients. Annual Review of Medicine, 34, 35-46.
46. Silberfarb, P.M., Philibert, D., & Levine, P.M. (1980). Psychosocial aspects of neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer patients. American Journal of Psychiatry, 137(5), 597-601.
47. Silverman, D.H., Castellon, S.A., Abraham, L., Dy, C.J., Pio, B.S., & Ganz, P.A. (2003, June). Abnormal regional brain metabolism in breast cancer survivors after adjuvant chemotherapy is associated with cognitive changes. Paper presented at the meeting of the American Society of Clinical Oncology, Los Angeles, CA.
48. Silverman, D.H., Dy, C.J., Castellon, S.A., Lai, J., Pio, B.S., Abraham, L., et al. (2007). Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Research and Treatment, 103(3), 303-311.
49. Tannock, I.F., Ahles, T.A., Ganz, P.A., & Van Dam, F.S. (2004). Cognitive impairment associated with chemotherapy for cancer: Report of a workshop. Journal of Clinical Oncology, 22(11), 2233-2239.
50. Wagner, L., Sweet, J. J., Butt, Z., Lai, J., and Cella, D. (in press). Measuring patient self-reported cognitive function: Qualitative findings and initial development of the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-COG) instrument. Journal of Supportive Oncology.
51. Wefel, J.S., Lenzi, R., Theriault, R.L., Davis, R.N., & Meyers, C.A. (2004). The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized longitudinal trial. Cancer, 100(11), 2292-2299.
52. Weiss, H.D., Walker, M.D., and Wirnik, P.H. (1974). Neurotoxicity of commonly used antineoplastic agents. The New England Journal of Medicine, 292, 75-81.
53. Wilson, C.J., Finch, C.E., & Cohen, H.J. (2002). Cytokines and cognition- The case for a head-to-toe inflammatory paradigm. Journal of the American Geriatric Society, 5(12), 2041-2056.
54. Yoshikawa, E., Matsuoka, Y., Inagaki, M., Nakano, T., Akechi, T., Kobayakawa, M., et al. (2005). No adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancer survivors. Breast Cancer Research and Treatment, 92(1), 81-84.